作者单位：
Egyptian Ministry of Health and Population, Central Administration for Pharmaceutical Affairs (Research Coordinator of ISoP Egypt Chapter in His Personal Capacity), Cairo, Egypt. mohamed.ahmed.elhawary19@gmail.com.
[1]
International Society of Pharmacovigilance (ISoP) Egypt Chapter, Cairo, Egypt. mohamed.ahmed.elhawary19@gmail.com.
[2]
International Society of Pharmacovigilance (ISoP) Africa Chapter, Abuja, Nigeria.
[3]
Utrecht Centre for Pharmaceutical Policy and Regulation, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University (General Secretary of ISoP Africa Chapter), Utrecht, The Netherlands.
[4]
International Society of Pharmacovigilance, ISoP Secretariat Ltd, London, UK.
[5]
International Society of Pharmacovigilance (ISoP) Latin America (LATAM) Chapter (General Secertary of ISoP), Quito, Ecuador.
[6]
Pharmacy Career Director of Pontificia, Universidad Javeriana (President of ISoP), Bogotá, Colombia.
[7]
International Society of Pharmacovigilance (ISoP) Africa Chapter, Kampala, Uganda.
[8]
National Drug Authority, Directorate of Product Safety (President of ISoP Africa Chapter), Kampala, Uganda.
[9]
International Society of Pharmacovigilance (ISoP) Middle East Chapter, Rabat, Morocco.
[10]
Centre Anti Poison et de Pharmacovigilance du Maroc, Rabat WHO Collaborating Centre, Rabat, Morocco.
[11]
International Society of Pharmacovigilance (ISoP) Egypt Chapter, Cairo, Egypt.
[12]
Faculty of Pharmacy, MSA University (President of ISoP Egypt Chapter), 6th of October City, Giza, Egypt.
[13]
DOI
10.1007/s40264-023-01363-8
PMID
37874450
发布时间
2023-11-29
换一批
换一批
